spruce biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.
Company profile
Ticker
SPRB
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
812154263
SPRB stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
S-8
Registration of securities for employees
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
13 Mar 24
8-K
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
8 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
Latest ownership filings
SC 13D/A
Novo Holdings A/S
28 Mar 24
SC 13G
Radoff Bradley Louis
28 Mar 24
SC 13D/A
Novo Holdings A/S
25 Mar 24
4
Change in insider ownership
25 Mar 24
SC 13D/A
Novo Holdings A/S
20 Mar 24
4
Change in insider ownership
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
SC 13D/A
Novo Holdings A/S
18 Mar 24
4
Change in insider ownership
18 Mar 24
4
Ralph William Charlton III
18 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 98.84 mm | 98.84 mm | 98.84 mm | 98.84 mm | 98.84 mm | 98.84 mm |
Cash burn (monthly) | (no burn) | (no burn) | 4.55 mm | 4.41 mm | 4.09 mm | 2.82 mm |
Cash used (since last report) | n/a | n/a | 31.13 mm | 30.16 mm | 27.96 mm | 19.26 mm |
Cash remaining | n/a | n/a | 67.71 mm | 68.67 mm | 70.87 mm | 79.57 mm |
Runway (months of cash) | n/a | n/a | 14.9 | 15.6 | 17.3 | 28.2 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 6 |
Closed positions | 11 |
Increased positions | 10 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 66.68 bn |
Total shares | 44.19 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Novo Holdings A/S | 6.72 mm | $14.45 bn |
5AM Opportunities II | 4.14 mm | $10.63 mm |
HealthCap VIII | 3.69 mm | $11.68 mm |
Armistice Capital | 3.50 mm | $7.52 bn |
RiverVest Venture Management | 2.94 mm | $6.31 bn |
CG Carlyle Group Inc | 2.90 mm | $6.23 bn |
Rock Springs Capital Management | 2.73 mm | $5.87 bn |
5AM Venture Management | 2.36 mm | $5.08 bn |
Omega Fund VI | 2.16 mm | $52.53 mm |
Omega Fund Management | 2.16 mm | $4.65 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Novo Holdings A/S | COMMON STOCK | Sell | Dispose S | No | No | 0.7547 | 465,021 | 350.95 k | 2,550,000 |
20 Mar 24 | Novo Holdings A/S | COMMON STOCK | Sell | Dispose S | No | No | 0.7336 | 359,979 | 264.08 k | 3,015,021 |
19 Mar 24 | Novo Holdings A/S | COMMON STOCK | Sell | Dispose S | No | No | 0.755 | 593,000 | 447.72 k | 3,375,000 |
18 Mar 24 | Novo Holdings A/S | COMMON STOCK | Sell | Dispose S | No | No | 0.7684 | 842,020 | 647.01 k | 3,968,000 |
14 Mar 24 | Samir M. Gharib | RSU Common Stock | Grant | Acquire A | No | No | 0 | 154,000 | 0.00 | 154,000 |
14 Mar 24 | Ralph William Charlton III | RSU Common Stock | Grant | Acquire A | No | No | 0 | 106,400 | 0.00 | 106,400 |
14 Mar 24 | Javier B. Szwarcberg | RSU Common Stock | Grant | Acquire A | No | No | 0 | 358,800 | 0.00 | 358,800 |
News
Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall
14 Mar 24
Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views
14 Mar 24
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
14 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
14 Mar 24
Crude Oil Moves Higher; Dollar General Posts Upbeat Earnings
14 Mar 24
Press releases
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
22 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
8 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
4 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
31 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
27 Mar 24